Gang Liu | Medicine and Health Sciences | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Gang Liu | Medicine and Health Sciences| Best Researcher Award

The Affiliated Hospital of Guizhou Medical University | China

Gang Liu, M.D., is a highly regarded Professor and Chief Physician of Orthopaedics at the Department of Emergency Orthopedics, The Affiliated Hospital of Guizhou Medical University. Serving also as a Master’s Supervisor, Dr. Liu has made substantial contributions to orthopaedic trauma care, with a clinical and academic career rooted in improving outcomes for patients with complex fractures and injuries. Known for his precision in surgical techniques and commitment to academic mentoring, he leads innovative research in trauma surgery and biomechanics. His leadership in the department reflects his dedication to clinical excellence, education, and advancing orthopaedic science. As an influential voice in orthopaedic medicine in China, Dr. Liu combines decades of hands-on experience with a forward-looking approach to research and treatment, helping shape the next generation of specialists in trauma care. His work bridges the gap between clinical application and academic research, fostering advancements in evidence-based orthopaedic medicine.

Profile

ORCID

Education

While specific educational details about Dr. Gang Liu are not publicly listed, his current academic and professional status indicates extensive medical training, including the attainment of a Doctor of Medicine (M.D.) degree, likely followed by specialized residency and fellowship programs in orthopaedic surgery. As a Professor and Chief Physician, he has undoubtedly completed postgraduate and professional training in trauma and emergency orthopaedics, biomechanics, and surgical innovation. His role as a Master’s Supervisor suggests strong academic foundations and consistent engagement with scholarly research. Dr. Liu is affiliated with Guizhou Medical University, where he likely received or has contributed significantly to medical education. His educational trajectory exemplifies the rigorous academic and clinical preparation typical of senior physician-scientists in China’s leading medical institutions. His expertise reflects years of advanced learning in both clinical practice and orthopaedic science, enabling him to train the next generation of surgeons and researchers with a firm grounding in trauma and biomechanics.

Experience

Dr. Gang Liu currently serves at the Affiliated Hospital of Guizhou Medical University in Guiyang, China, where he is a Professor, Chief Physician in Orthopaedics, and a Master’s Supervisor. With decades of clinical and teaching experience, he plays a pivotal role in emergency orthopaedics, specializing in trauma management and fracture treatment. His leadership in the Department of Emergency Orthopedics involves not only patient care but also surgical innovation and departmental development. Dr. Liu has extensive experience in applying biomechanics to orthopaedic practice, aligning clinical strategies with research-based methodologies. His commitment to teaching and mentoring graduate students positions him as a key academic figure within the university. He integrates research, clinical service, and academic mentorship, demonstrating a rare balance of practical and theoretical knowledge in orthopaedics. His experience reflects the depth of his involvement in complex surgical procedures, clinical trials, and strategic planning for orthopaedic care in academic hospital settings.

Awards and Honors

Although detailed information on Dr. Gang Liu’s specific awards and honors is not publicly disclosed, his distinguished titles—Professor, Chief Physician, and Master’s Supervisor—indicate recognition for excellence in clinical practice, education, and research. Such positions in China’s medical hierarchy are awarded based on years of exceptional service, academic contributions, and leadership in healthcare delivery. It is likely that Dr. Liu has received institutional commendations and possibly regional or national recognition for his work in trauma and fracture care. His role in mentoring postgraduates suggests academic honors or commendations for teaching and research guidance. His contributions to biomechanics research and emergency orthopaedics may have earned him research grants or hospital-level awards for innovation or service excellence. As a senior figure at the Affiliated Hospital of Guizhou Medical University, he exemplifies the attributes of a respected physician-scientist whose reputation is built on both clinical outcomes and contributions to the academic and research mission of the institution.

Research Focus

Dr. Gang Liu’s research focuses on trauma, fracture management, and biomechanics in orthopaedic medicine. His work aims to improve understanding of the mechanical and biological responses of bone and soft tissue to injury, optimizing both surgical techniques and recovery outcomes. He explores how trauma impacts musculoskeletal function and how biomechanics can inform fracture fixation and healing strategies. At the Department of Emergency Orthopedics, Dr. Liu integrates research into clinical practice, conducting translational studies that advance evidence-based protocols in trauma care. His investigations likely include experimental and clinical trials, examining both traditional and modern surgical interventions. Emphasizing interdisciplinary collaboration, his research contributes to innovations in implant design, bone regeneration, and trauma surgery protocols. As a Master’s Supervisor, he mentors students on research methodologies, encouraging rigorous scientific exploration in orthopaedics. Dr. Liu’s research strengthens the link between clinical need and scientific discovery in the rapidly evolving field of emergency orthopaedic care.

Conclusion

Dr. Gang Liu stands as a dedicated leader in orthopaedic trauma care, combining clinical expertise, academic mentorship, and biomechanical research to improve patient outcomes and train future surgeons.

Muhammad Zia | Pharmacology | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Muhammad Zia | Pharmacology | Best Researcher Award

College of staten island | United States

Dr. Muhammad K. Zia is a medical professional and educator specializing in biological and medical sciences, currently serving as a Doctoral Lecturer in the Department of Biology at the College of Staten Island/CUNY. With an M.B.B.S. from Jinnah Sindh Medical University, Dr. Zia brings over two decades of diverse experience spanning clinical practice, higher education, and scientific research. He has contributed significantly to undergraduate science education through positions at Kean University, Fairleigh Dickinson University, and other academic institutions. His clinical background includes roles in pathology and diabetology in both the U.S. and Pakistan. Notably, he was awarded the PSC-CUNY research grant to study the effects of angiotensin receptor blockers on diabetic nephropathy. A dedicated mentor and presenter, Dr. Zia has supervised multiple student research posters and actively contributes to academic development at CSI. His interdisciplinary expertise uniquely bridges clinical knowledge with life science education and research.

Profile

ORCID

Education

Dr. Muhammad K. Zia earned his medical degree (M.B.B.S.) from Jinnah Sindh Medical University in Karachi, Pakistan. His training equipped him with a solid foundation in clinical medicine, including internal medicine, diagnostics, pathology, and patient care. Following graduation, he pursued additional clinical training and gained certification to practice medicine in Pakistan. Over time, he transitioned into academic medicine, combining his clinical expertise with pedagogy in biological sciences. He has complemented his education with ongoing professional development and has contributed to academic settings through student mentorship, course delivery, and research guidance. His deep understanding of clinical biology, pathology, and pharmacological interventions forms the basis of his teaching philosophy. While he holds no formal advanced academic degrees beyond his medical license, Dr. Zia has consistently demonstrated a commitment to educational excellence and medical scholarship, as evidenced by his active teaching roles and scholarly contributions in academic institutions in both the U.S. and abroad.

Experience

Dr. Zia’s professional journey reflects a balanced blend of academic instruction and clinical medicine. He has served as a Doctoral Lecturer at the College of Staten Island, following 12 years as an adjunct and substitute instructor. His teaching experience also spans Kean University, Union County College, Stevens Institute of Technology, and Wagner College, where he taught various biology and medical science courses. In the clinical domain, Dr. Zia has worked as a Medical Assistant in New Jersey, a Pathology Assistant at QDx Pathology Services, and held roles such as Associate Diabetologist and Resident Medical Officer at Baqai Medical University. Earlier in his career, he served as a Clinical Assistant at Imam Clinic in Karachi. His clinical responsibilities included diagnostics, treatment planning, minor procedures, and patient education. This extensive experience across multiple institutions showcases his ability to deliver science education enriched by real-world medical practice.

Awards and Honors

Dr. Muhammad K. Zia has been recognized for his commitment to academic research and mentorship through the PSC-CUNY Cycle 54 Research Grant. The award supported his study on the effects of Angiotensin Receptor Blockers in diabetic nephropathy, showcasing his initiative in clinical and retrospective research. His efforts to promote scientific inquiry among undergraduates were further highlighted through his supervision of multiple poster presentations at the CSI Undergraduate Conference on Research, Scholarship, and Arts. These included literature reviews on SGLT2 inhibitors, Parkinson’s disease interventions, and cardiovascular risks linked to supraventricular tachycardia. Dr. Zia has also presented workshops such as “How to Write a Reference Letter to Support Pre-Med Students,” contributing to the academic development of aspiring physicians. While he may not yet have amassed a wide array of traditional academic honors, his consistent involvement in student mentorship, curriculum enrichment, and funded research speaks volumes about his dedication and impact.

Research Focus

Dr. Zia’s research interests center on the intersection of clinical medicine and chronic disease management. His primary focus includes diabetic complications, particularly diabetic nephropathy and the therapeutic role of angiotensin receptor blockers. He is also interested in cardiovascular pharmacology and endocrinology, as demonstrated by his guidance of student research on SGLT2 inhibitors and their cardioprotective effects. His approach often involves retrospective chart reviews and critical literature analysis using credible medical databases like PubMed and the European Journal of Medicine. He further engages in collaborative educational research and academic mentoring, particularly within undergraduate settings. Dr. Zia’s supervised projects span diverse clinical areas, such as Parkinson’s disease interventions and arrhythmia outcomes, reflecting his broad scientific curiosity and integrative knowledge of pathophysiology. Through these initiatives, he fosters critical thinking and evidence-based research skills among students, contributing to a stronger foundation in translational medicine and interdisciplinary health sciences education.

Publications

Title: Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study
Year: 2025

Conclusion

Dr. Muhammad K. Zia’s multidimensional career—rooted in clinical medicine and expanded through academic instruction and student mentorship—demonstrates a sustained commitment to bridging medical science with impactful education and applied research.

Neha Verma | Biotechnology | Best Researcher Award

Published on by Cognitive Scientist Awards

Ms. Neha Verma | Biotechnology | Best Researcher Award

Sharda University | India

Neha Verma is a dedicated biotechnology researcher currently pursuing her Ph.D. at Sharda University, research experience in molecular biology, cell culture, spectroscopy, and bioinformatics. She has significantly contributed to cancer and osteoporosis research, with numerous publications in reputed journals and several patents to her credit. Her expertise encompasses a range of technical proficiencies including FACS, RT-PCR, HPLC, GC-MS, LC-MS, NMR, FT-IR, and advanced microscopy. She has actively participated in multiple national and international conferences and workshops, earning recognition for her work. She has co-authored book chapters with reputed publishers like Elsevier and is the recipient of prestigious awards such as Best Oral Presentation, Best Research Scholar, Silver Medal, and Young Scientist Award. Neha’s research blends experimental biology with computational techniques, reflecting a multidisciplinary approach. With a commitment to innovation and translational research, she aims to make meaningful contributions to biomedical sciences through novel therapeutic strategies.

Profile

Googlescholar

 Education

Neha Verma has built a strong academic foundation in the life sciences and biotechnology domain. She is currently pursuing her Ph.D. in Biotechnology with coursework from the Department of Life Sciences at Sharda University, where her research involves a multidisciplinary approach combining cell culturing, phytochemical analysis, and bioinformatics modeling. Prior to this, she earned her M.Sc. in Biotechnology from Himalayan University, where she developed core competencies in laboratory techniques and research methodologies. She began her academic journey with a B.Sc. in Life Sciences, which laid the groundwork for her interest in molecular biology and biochemistry. Throughout her education, she has consistently demonstrated academic excellence, contributing to scientific publications, attending scientific forums, and actively engaging in workshops and webinars related to spectroscopy, AI tools in science, and genetic disorders. Her academic path reflects a progressive learning trajectory that aligns closely with her current research goals and future aspirations in translational biotechnology

Experience

Neha Verma possesses over five years of extensive hands-on research experience in biotechnology, particularly in molecular biology, animal cell culturing, and the isolation and application of plant-based bioactives. Her professional exposure spans several advanced analytical and spectroscopic platforms such as HPLC, GC-MS, LC-MS, NMR, and FT-IR, used primarily for metabolite profiling and compound identification. She has worked on osteogenic differentiation and anticancer studies using plant extracts, evidenced by her co-authorship on high-impact journal articles and patented innovations. She has cultivated skills in experimental planning, data analysis using GraphPad and Excel, and bioinformatics tools like molecular docking and Swiss target prediction. Neha has participated in several high-end workshops funded by DST-SERB and DBT, as well as training programs on good laboratory practices and 3D cell culture technology. Her experience also includes contributing to international book chapters and conference presentations, showcasing her commitment to knowledge dissemination and interdisciplinary research collaboration.

Awards and Honors

Neha Verma has earned multiple prestigious awards recognizing her research excellence and scientific contributions. She received the Best Oral Presentation Award at a DBT-funded National Conference focused on Disease Diagnosis and Drug Development.  she was honored with the Best Research Scholar Award at the 6th International Conference on Cutting-edge Solutions in Science, Technology, Engineering, and Humanities. Her achievements also include receiving the Silver Medal at the 8th Annual Meeting of the International Association of Zoologists and the 5th International Conference on Recent Trends in Life Sciences and Biotechnology. Additionally, she was conferred the Young Scientist Award at the 4th Annual Meeting of the International Association of Zoologists. These accolades reflect her sustained efforts in innovative biotechnology research, her impactful presentations at scientific forums, and her leadership in driving translational outcomes. Her work in cancer and osteoporosis research has consistently gained academic and peer recognition.

Research Focus

Neha Verma’s research is centered on biotechnology applications in cancer and osteoporosis, particularly through the use of plant-derived bioactive compounds. She investigates the therapeutic potential of phytochemicals on osteogenic differentiation and anticancer activity, integrating molecular biology techniques like RT-PCR and FACS with spectroscopic tools such as HPLC, GC-MS, LC-MS, and NMR for compound analysis. Her studies also extend to bioinformatics, where she employs molecular docking and target prediction to elucidate mechanistic pathways. Neha’s scientific approach is highly interdisciplinary, blending traditional ethnopharmacology with modern experimental and computational methods. Her work has led to several granted and published patents focusing on anticancer and anti-osteoporotic agents. With contributions to journals, conferences, and book chapters, she aims to bridge the gap between natural products research and clinical translational outcomes in biotechnology.

Publications

 

Title: Occupational health hazards and wide spectrum of genetic damage by the organic solvent fumes at the workplace: A critical appraisal
Year: 2022
Citations: 10

Title: Recent Update on Active Biological Molecules in Generating the Anticancerous Therapeutic Potential of Garcinia mangostana
Year: 2022
Citations: 9

Title: A review on therapeutic mechanism of medicinal plants against osteoporosis: effects of phytoconstituents
Year: 2023
Citations: 6

Title: Sustainable synthesis of magnetic nanoparticles: biological applications of Cedrus deodara extract
Year: 2025
Citations: 1

Conclusion

Neha Verma is an accomplished biotechnology researcher whose interdisciplinary expertise, impactful publications, patents, and awards reflect her commitment to advancing therapeutic innovations in cancer and osteoporosis through integrated experimental and computational approaches.

Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Dr. Jim Jinn-Chyuan Sheu is a professor at the Institute of Biomedical Sciences, National Sun Yat-sen University, Taiwan, and an adjunct professor in several prestigious institutions. With a PhD in Life Science from National Tsing-Hua University, his academic and industrial experiences span cancer genetics, precision medicine, and biopharmaceuticals. He has held positions at Johns Hopkins Medical Institutions and Development Center for Biotechnology. His research explores molecular mechanisms underlying diseases such as cancer and endometriosis, employing genome-wide technologies to identify biomarkers and drug targets. He actively contributes to biomedical innovation, translational medicine, and mentorship. Dr. Sheu has received numerous national and international awards, including the Wu-Da-You Memorial Award and Sigma Xi membership. He is also an ambassador for the European Association for Cancer Research. As a prolific researcher and reviewer, he plays key roles in research councils and institutional review boards, helping shape scientific policy and translational biomedical advancements in Taiwan and beyond.

Profile

Education 🎓

Dr. Sheu earned his Ph.D. in Life Science from National Tsing-Hua University, Taiwan, in 2002, where he focused on advanced molecular biology, gene expression regulation, and biomedical research. His doctoral training provided a strong foundation in cancer genetics and systems biology. Earlier, he completed his B.S. in Biology (now Life Science) from Fu-Jen University in 1994, building core competencies in biological sciences and cellular mechanisms. These educational milestones equipped him with theoretical knowledge and technical skills in genomics, proteomics, and cellular signaling, which are now reflected in his research on chromatin remodeling, cancer biomarkers, and therapeutic targets. Through rigorous academic mentorship, Dr. Sheu gained early exposure to multidisciplinary research and critical analysis, fostering his interest in precision medicine. His academic background laid the groundwork for his contributions to biomedical research, drug development, and translational science. These formative years in Taiwan’s top universities underpin his long-standing excellence in scientific discovery and innovation.

Experience 👨‍🏫

Dr. Sheu’s professional experience includes faculty roles and research leadership across academia and industry. He has served as a Professor at National Sun Yat-sen University since 2014 and previously held faculty roles at China Medical University. Internationally, he was a Research Fellow at Johns Hopkins Medical Institutions (2004–2006). Between 2003–2004, he worked in various leadership positions at the Development Center for Biotechnology, including Director of Protein Drugs Division and Project Leader. His postdoctoral and early research roles included work with Dr. Tse-Wen Chang and Dr. Carmay Lim at Academia Sinica. His academic leadership includes roles such as Associate VP of R&D, Chair of the Institute of Biomedical Sciences, and Director of Research Resources at NSYSU. He has reviewed research proposals for numerous hospitals and institutions, served on IRBs, and guided government research policy. His diverse experience bridges basic science, translational research, and biomedical entrepreneurship with national and global impact.

Awards & Recognitions 🏅

Dr. Sheu has received over 30 prestigious awards. In 2023 alone, he earned the Tien-Te Lee Award, NSYSU Outstanding Faculty Award, and top honors at the 37th Joint Biomedical Conference. He previously received the Prof. Chii-Ruey Tzeng Award, Sigma Xi membership (2021), and EACR Ambassador role (2020). His innovation was recognized by Future Tech Award and the 2020 Smart Life Innovation Competition. His studies were featured as Taiwan Research Highlights and F1000Prime recommendations. He was the 2014 recipient of the Wu-Da-You Memorial Award and the IBC Outstanding Scientific Achievement Award. He received the Medical Young Investigator Award in 2009 and the Best Basic Science Award at Johns Hopkins in 2005. As a government-financed scholar to the U.S., his academic excellence has been internationally recognized. He consistently ranks among Taiwan’s top biomedical researchers, illustrating his impact through award-winning research in endometriosis, cancer stemness, diagnostics, and therapeutic innovation.

Research Interests 🔬

Dr. Sheu’s research focuses on cancer genetics and genomics, endometriosis, precision medicine, chromatin remodeling, cytoskeletal dynamics, cell adhesion and invasion, and mechanotransduction. His lab investigates how abnormalities in gene expression and chromatin structure drive disease progression, especially in gynecologic cancers and endometriosis. By applying genome-wide analysis and bioinformatics, his team identifies disease-driving genes and develops novel diagnostic tools and therapeutic strategies. A key interest is the tumor microenvironment and how cytoskeletal networks and nuclear architecture influence cancer stemness and metastasis. His group explores traditional Chinese medicine compounds and stem cell therapies, advancing integrative approaches to medicine. Antibody and vaccine engineering are also integral to his translational pipeline. Funded by NSTC Taiwan and other institutions, his projects target non-invasive diagnostics and biomarker-based interventions. His long-term vision involves bridging molecular biology, clinical application, and therapeutic innovation to impact patient care and global health through interdisciplinary and precision-driven biomedical science.

Publications

Shilpa Kumari | Biotechnology | Best Researcher Award

Published on by Cognitive Scientist Awards

Ms.Shilpa Kumari | Biotechnology | Best Researcher Award

 

Sharda University, India

Profile

Education

She is currently pursuing a Ph.D. at Sharda University since 2020, having completed her coursework with an impressive 84.5%. She holds an M.Sc. in Biotechnology from Chandigarh University, where she secured 79.6% in 2019. Prior to that, she earned her B.Sc. from HNB Garhwal Central University, Srinagar, in 2017 with a score of 66.7%. She completed her 12th grade in the Medical stream under CBSE in 2014 with 74.4% and her 10th grade in General Science in 2012, securing 75.5%.

 

Awards

She has been awarded the Sharda University Research Scholarship (SURS) by Sharda University since February 2021. She received a Silver Medal at the 8th Annual Meeting of the International Association of Zoologists and the 5th International Conference on Recent Trends in Life Sciences and Biotechnology held at Maharishi Markandeshwar (Deemed to be University), Haryana, in December 2024. Additionally, she was granted International Travel Support from the Science and Engineering Research Board (SERB), Department of Science and Technology, Government of India, to present her research at the University Malay, Kuala Terengganu, Malaysia, in August 2024. She secured 2nd Prize at the Anveshan International Convention 2023-2024 (North Zone), organized by the Association of Indian Universities (AIU) in January 2024. Furthermore, she won the Best Oral Presentation Award at the National Conference on Disease Diagnosis and Drug Development Against Human Pathogens, sponsored by DBT and organized by Muthyammal College of Arts and Science in November 2023.

Book chapters

1. Shilpa Kumari, Neha Verma, Anil Kumar, Sunita Dalal, and Kanu Priya. “Functional
overrepresentation analysis and their application in microbial pathogenesis.” In Systems Biology
Approaches for Host-Pathogen Interaction Analysis, pp. 171-179. Academic Press, 2024.
2. Neha Verma, Shilpa Kumari, Anil Kumar, and Kanu Priya. “Advancements in systems biologybased analysis of microbial pathogenesis.” In Systems Biology Approaches for Host-Pathogen
Interaction Analysis, pp. 181-190. Academic Press, 2024

Publication

Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

Published on by Cognitive Scientist Awards

Mr. Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

PhD Scholar at Acharya and BM Reddy College of Pharmacy, Bengaluru, India

Mr. Rohit Pal is a dedicated and emerging researcher in the field of pharmaceutical sciences, particularly focusing on drug discovery and development. Currently pursuing his Ph.D. at Acharya & BM Reddy College of Pharmacy in Bengaluru, he is engaged in innovative research on Pyrimidine derivatives as fourth-generation EGFR inhibitors to combat Non-Small Cell Lung Cancer (NSCLC). With a strong academic background, including an M.Pharmacy in Pharmaceutical Chemistry, Mr. Pal combines his expertise in chemical synthesis with cutting-edge computational techniques like molecular docking and structure-activity relationship (SAR) analysis. His work spans multiple research areas, including anticonvulsant activity, anti-inflammatory research, and the pharmacognostic standardization of endangered species like Passiflora vitifolia. Throughout his career, Mr. Pal has demonstrated a capacity for both in-silico drug design and experimental testing, balancing theoretical approaches with hands-on experimentation. His impressive publication record in respected journals further showcases his capability to contribute to the scientific community. As a promising young researcher, Mr. Pal’s ongoing work not only advances pharmaceutical sciences but also holds potential for meaningful clinical applications in cancer therapy and drug design.

Profile

Orcid

 

Education 🎓

Mr. Rohit Pal’s educational background demonstrates a consistent pursuit of excellence in the field of pharmaceutical sciences. He is currently enrolled in a Ph.D. program at Acharya & BM Reddy College of Pharmacy in Bengaluru, Karnataka, where his research is focused on the development of Pyrimidine derivatives as EGFR inhibitors to target Non-Small Cell Lung Cancer (NSCLC). Prior to his doctoral studies, Mr. Pal completed his M.Pharmacy in Pharmaceutical Chemistry from ISF College of Pharmacy in Moga, Punjab, achieving a notable CGPA of 9.07. His academic journey began with a B. Pharmacy from Dev Bhoomi Institute of Pharmacy and Research, Dehradun, where he gained a robust foundation in pharmaceutical sciences. Additionally, Mr. Pal holds a D. Pharmacy from SGGS College of Pharmacy, Chandigarh, further demonstrating his dedication to the field from the onset of his academic career. His varied educational experiences have shaped his interdisciplinary approach to pharmaceutical research, combining knowledge from chemistry, biology, and computational sciences. This solid academic foundation has propelled Mr. Pal to explore complex drug development challenges, particularly in cancer therapy, with a keen interest in molecular-level drug interactions.

Work Experience 💼

Mr. Rohit Pal’s professional experience reflects a promising trajectory in pharmaceutical research and drug discovery. As a Ph.D. scholar at Acharya & BM Reddy College of Pharmacy, he is deeply involved in researching Pyrimidine derivatives for EGFR inhibition in Non-Small Cell Lung Cancer (NSCLC). His research explores the design, synthesis, and evaluation of novel drug candidates, combining in-vitro testing with computational drug design. Through the use of molecular docking and structure-activity relationship (SAR) analysis, Mr. Pal aims to identify compounds with high therapeutic potential. Beyond his Ph.D. work, Mr. Pal has worked on various other research projects, including 1,2,4-triazine derivatives for anticonvulsant activity and the anti-inflammatory properties of Passiflora vitifolia, an endangered plant species. His work spans both synthetic chemistry and biological testing, allowing him to gain expertise in pharmacological assays and computational modeling. Mr. Pal’s professional experience also includes using sophisticated instruments such as HPLC, UV spectrophotometers, and Microwave Synthesizers, which complement his experimental work and ensure the reliability of his results. These experiences have positioned him well for future leadership roles in pharmaceutical research and drug developmen

Awards and Honors

Although still in the early stages of his academic career, Mr. Rohit Pal has already garnered significant recognition for his research efforts. His academic excellence is reflected in his M.Pharmacy CGPA of 9.07, placing him among the top students in his cohort. Mr. Pal’s research has been published in reputable journals such as the Journal of Biomolecular Structure and Dynamics and Chemical Physics Impact, demonstrating the impact and quality of his work. These publications are indicative of his ability to produce research that contributes to the scientific community. Despite being early in his career, his involvement in cutting-edge research on Pyrimidine derivatives and EGFR inhibitors has already gained attention within the academic and pharmaceutical fields. His dedication to molecular docking, drug design, and pharmacognostic studies positions him for further recognition. As Mr. Pal continues to contribute to innovative drug development solutions, he is likely to receive more prestigious awards and honors, reflecting the growing importance of his work in cancer research and pharmaceutical chemistry.

Research Interests

Mr. Rohit Pal’s research interests are centered around the intersection of pharmaceutical chemistry and drug discovery. His primary focus is on developing Pyrimidine derivatives as fourth-generation EGFR inhibitors aimed at Non-Small Cell Lung Cancer (NSCLC), a serious health concern with limited therapeutic options. By targeting the epidermal growth factor receptor (EGFR), his work could offer more effective treatment alternatives for cancer patients. In addition to cancer research, Mr. Pal has explored 1,2,4-triazine derivatives for evaluating anticonvulsant activity, contributing to neurological disorder treatments. He is also interested in anti-inflammatory research, with a particular focus on Passiflora vitifolia, an endangered plant species, aiming to standardize its pharmacognostic properties. His multidisciplinary approach extends to the application of computational drug design, where he utilizes molecular docking and molecular dynamics simulations to predict drug-receptor interactions. Mr. Pal is committed to advancing drug development by combining experimental chemistry with in-silico methodologies, offering innovative solutions for complex healthcare challenges. His work on drug repurposing, targeted therapies, and sustainable drug sourcing reflects his holistic approach to addressing both scientific and global health concerns.

Research Skills

Mr. Rohit Pal possesses a wide range of research skills essential for successful pharmaceutical research. His proficiency in chemical synthesis includes techniques such as recrystallization, sublimation, and flash chromatography, which he applies to purify and isolate new compounds for testing. In addition to these laboratory techniques, Mr. Pal is highly skilled in analytical methods, including HPLC and UV spectrophotometry, to assess the purity and chemical composition of compounds. He is also adept at utilizing computational tools for drug design, particularly AutoDock, Biovia Drug Discovery Studio, and Pymol, to perform molecular docking and molecular dynamics simulations. These tools allow him to predict the interactions between drug candidates and their targets, enhancing the efficiency of drug development. Furthermore, Mr. Pal has experience in in-vitro biological testing, including assays for anticonvulsant, anti-inflammatory, and antioxidant activities, ensuring the biological relevance of his synthesized compounds. His ability to combine experimental techniques with computational modeling equips him to approach drug discovery from both theoretical and practical angles, ensuring well-rounded and impactful research outcomes.

📚 Publications

  • Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: In-vitro and in-silico exploration
    • Journal: Journal of Molecular Structure
    • DOI: 10.1016/j.molstruc.2024.141227
    • Date: April 2025
    • Contributors: Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Ghanshyam Teli; Viney Chawla; Pooja A. Chawla
  • Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.117034
    • Date: January 2025
    • Contributors: Ebna Azizal Omar; Rajesh R.; Pronoy Kanti Das; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Lalmohan Maji
  • Benzothiazole a privileged scaffold for cutting-edge anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.116831
    • Date: December 2024
    • Contributors: Aayishamma I; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Abhishek Ghara; Nimmagadda Venkata Satya Sai Aishwarya; Kumaraswamy B; Ketan R. Hosamani; Manjushree B V; Haripriya E
  • An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
    • Journal: Journal of Biomolecular Structure and Dynamics
    • DOI: 10.1080/07391102.2023.2252082
    • Date: December 11, 2024
    • Contributors: Rohit Pal; Ghanshyam Teli; Sindhuja Sengupta; Lalmohan Maji; Gurubasavaraja Swamy Purawarga Matada
  • Exploring the anticancer potential of triazine derivatives: An outlook of designing strategies, docking studies, and structure-activity relationships (SAR)
    • Journal: ChemistrySelect
    • DOI: 10.1002/slct.202402766
    • Date: November 2024
    • Contributors: B. V. Manjushree; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Md. Ashadul Sk; M. P. Viji; Nimmagadda Venkata Satya Sai Aishwarya; Pronoy Kanti Das; I. Aayishamma; S. Mounika
  • Pyrazole, pyrazoline, and fused pyrazole derivatives: New horizons in EGFR-targeted anticancer agents
    • Journal: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202400880
    • Date: November 2024
    • Contributors: Ketan R Hosamani; Hemalatha K; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Kumaraswamy B; Aayishamma I; Nimmagadda Venkata Satya Sai Aishwarya

Conclusion 

Mr. Rohit Pal is an exceptionally talented and promising researcher in the field of pharmaceutical sciences. His research, focused on Pyrimidine derivatives as EGFR inhibitors for Non-Small Cell Lung Cancer (NSCLC), is not only innovative but holds significant promise for advancing cancer treatment. His combination of chemical synthesis, computational drug design, and biological testing reflects his multidisciplinary approach to pharmaceutical research. Mr. Pal’s commitment to anti-inflammatory, anticonvulsant, and pharmacognostic standardization further demonstrates his versatility as a researcher. While still in the early stages of his career, his publication record and expertise in molecular docking and drug design suggest that he is well on his way to becoming a leader in pharmaceutical research. His ongoing work could contribute to groundbreaking advancements in cancer therapy, neurological disorder treatments, and sustainable drug sourcing. With his strong educational background, solid professional experience, and growing body of work, Mr. Rohit Pal is undoubtedly a candidate with the potential to make meaningful contributions to drug development and global health. His future in research looks bright, and he is well-positioned for recognition in upcoming awards such as the Young Scientist Award.